Jodar E, Michelsen M, Polonsky WH, Rea R, et al. Semaglutide improves health-related quality of life vs placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6). Diabetes Obes Metab 2020 Mar 30. doi: 10.1111/dom.14039.
PMID: 32227613